There is a desperate need for novel therapies to improve the clinical outcome of TNBC. Imugene expects CHECKvacc to provide an improved outcome for women diagnosed with TNBC each year. Last year, the City of Hope® dosed the second patient in the Phase I clinical trial of CHECKvacc. Watch this video on Kalkine TV.
Imugene Limited tapping breast cancer market via oncolytic virus CHECKvacc
GET A FREE STOCK REPORT
Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.
Be the First to Comment